TAKEDA PHARMACEUTICAL CO LTD (TAK) Form 6-K — Jul 30, 2026

Takeda Pharmaceutical reported mixed Q1 FY2026 results with revenue of JPY 1,219.9 billion, up 10.2% on an actual exchange rate basis but down 0.5% on a constant currency basis. The revenue increase was primarily driven by favorable foreign exchange impacts from the depreciation of the Japanese yen, while underlying business volume showed minimal growth. Net profit for the period declined 8.9% year-over-year to JPY 113.2 billion, with basic EPS falling to JPY 71.65 from JPY 79.40 in the prior year period. The decline in profitability was attributed to higher tax expenses related to reassessment of deferred tax assets and increased restructuring costs of JPY 35.8 billion.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.